Comparison of survival outcomes in patients with disseminated disease according to the treatment strategy. OS (A) and PFS (B) did not differ between the surgery/chemotherapy and chemotherapy groups. However, comparison according to the use of rituximab showed longer OS (C) and PFS (D) in patients treated with R-CHOP than in those treated with CHOP.